« Previous
Next »
Journal of Cardiac Failure
Volume 15, Issue 3
, Pages
199-205
, April 2009
Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?
To access this article, please choose from the options below
Pfizer Inc. provided an unrestricted educational grant to CIC INSERM-CHU of Nancy, France, to support the workshop from which this manuscript was generated (coordinator: Faiez Zannad).
Conflict of interest: None.
PII: S1071-9164(08)01053-1
doi: 10.1016/j.cardfail.2008.10.029
© 2009 Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Cardiac Failure
Volume 15, Issue 3
, Pages
199-205
, April 2009
